
    
      Constipation is a common gastrointestinal problem estimated to effect 2-27 % of the
      population in United States . It is found more commonly in women and elderly . The prevelance
      of constipation and growing demand for treatment dictate the need for safe and effective
      treatment options . Lubiprostone is the first chloride channel activator approved by FDA for
      long term treatment of chronic idiopathic constipation in adult men and women . To provide a
      generic medicine to the U.S population Dr Reddy's Laboratories intends to conduct this study
      to evaluate that the Lubiprostone manufactured by it is equally effective and safe as
      marketed AMITIZAÂ® ( Lubiprostone) 24 mcg capsules (Sucampo Pharmaceuticals, Inc.)
    
  